23067-79-0

Basic information

• Product Name: 8-tert-butylchroman-4-one
• Synonyms: 8-tert-butylchroman-4-one;8-(tert-butyl)-2,3-dihydro-4H-1-benzopyran-4-one
• CAS NO: 23067-79-0
• Molecular Formula: C13H16O2
• Molecular Weight: 204.26494
• Mol File: 23067-79-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 323.935°C at 760 mmHg
• Flash Point: 141.85°C
• Appearance: /
• Density: 1.072
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.527
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 8-tert-butylchroman-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 8-tert-butylchroman-4-one(23067-79-0)
• EPA Substance Registry System: 8-tert-butylchroman-4-one(23067-79-0)

Safety Data

• Hazardous Substances Data: 23067-79-0(Hazardous Substances Data)

Usage

General Description

8-Tert-butylchroman-4-one, also known as trolox, is a synthetic derivative of vitamin E that is commonly used as an antioxidant in food and cosmetic products. It is a white crystalline powder with a molecular formula of C15H22O2 and a molecular weight of 234.33 g/mol. Trolox is highly soluble in water and is stable under normal conditions, making it a popular choice for extending the shelf life of various products. Its antioxidant properties are attributed to its ability to scavenge free radicals and protect against oxidative stress, making it a valuable ingredient in the formulation of anti-aging and skincare products. Additionally, trolox has been studied for its potential therapeutic uses in the treatment of various diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions.

InChI:InChI=1/C13H16O2/c1-13(2,3)10-6-4-5-9-11(14)7-8-15-12(9)10/h4-6H,7-8H2,1-3H3

Upstream product

• 88-18-6 2-tert-Butylphenol 
• 55619-88-0 1-(tert-butyl)-2-(prop-2-yn-1-yloxy)benzene 
• 890839-78-8 1-(tert-Butyl)-2-((3-chloroprop-2-yn-1-yl)oxy)benzene 

Downstream Products

• 1221444-51-4 (R)-8-tert-butylchroman-4-amine 
• 1228553-77-2 C₁₃H₁₉NO 

Relevant articles and documents

Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases

The invention provides modulators for the orphan nuclear receptor RORγ and methods for treating RORγ mediated diseases by administrating these novel RORγ modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.

Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists

Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition.

TRPV1 ANTAGONISTS

Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.